These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36513818)

  • 41. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
    Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF
    Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    J Comput Assist Tomogr; 2015; 39(5):810-5. PubMed ID: 26035406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
    Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Prognostic Utility of
    Li C; Yu H; Chen X; Han S; Peng S; Lei T; Yang H
    Front Oncol; 2022; 12():772773. PubMed ID: 35677166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
    Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
    BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
    Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
    Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline [
    Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma.
    Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC
    Medicine (Baltimore); 2018 Jan; 97(2):e9513. PubMed ID: 29480842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 54. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
    Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T
    Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
    Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
    Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.
    Winkelmann M; Bücklein VL; Blumenberg V; Rejeski K; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    Front Oncol; 2022; 12():974029. PubMed ID: 36158658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
    Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
    Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
    Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.